- Home
- IVR vs ABUS Comparison
IVR vs ABUS Comparison
Compare IVR & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVR
- ABUS
- Stock Information
- Founded
- IVR 2008
- ABUS N/A
- Country
- IVR United States
- ABUS United States
- Employees
- IVR N/A
- ABUS N/A
- Industry
- IVR Real Estate Investment Trusts
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- IVR Real Estate
- ABUS Health Care
- Exchange
- IVR Nasdaq
- ABUS Nasdaq
- Market Cap
- IVR 535.6M
- ABUS 629.1M
- IPO Year
- IVR 2009
- ABUS N/A
- Fundamental
- Price
- IVR $8.88
- ABUS $3.42
- Analyst Decision
- IVR Buy
- ABUS Strong Buy
- Analyst Count
- IVR 3
- ABUS 4
- Target Price
- IVR N/A
- ABUS $5.50
- AVG Volume (30 Days)
- IVR 1.2M
- ABUS 646.4K
- Earning Date
- IVR 02-20-2025
- ABUS 03-03-2025
- Dividend Yield
- IVR 18.02%
- ABUS N/A
- EPS Growth
- IVR N/A
- ABUS N/A
- EPS
- IVR 0.65
- ABUS N/A
- Revenue
- IVR $79,359,000.00
- ABUS $6,742,000.00
- Revenue This Year
- IVR N/A
- ABUS N/A
- Revenue Next Year
- IVR $8.53
- ABUS N/A
- P/E Ratio
- IVR $13.66
- ABUS N/A
- Revenue Growth
- IVR 1793.56
- ABUS N/A
- 52 Week Low
- IVR $7.48
- ABUS $2.30
- 52 Week High
- IVR $9.97
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- IVR 63.38
- ABUS 54.07
- Support Level
- IVR $8.32
- ABUS $3.24
- Resistance Level
- IVR $8.71
- ABUS $3.44
- Average True Range (ATR)
- IVR 0.18
- ABUS 0.12
- MACD
- IVR 0.04
- ABUS 0.01
- Stochastic Oscillator
- IVR 78.05
- ABUS 55.56
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.